A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas

Brief description of study

This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.


Clinical Study Identifier: s22-01504
ClinicalTrials.gov Identifier: NCT05669482
Principal Investigator: Kristen Spencer.
Other Investigators: Daniel J Becker, Carol M Lee, Jonathan B Kahn, Keriann M Scavone, Nina Beri, Jennifer Chuy, Paul E. Oberstein, Rafael Winograd, Shun Yu.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.